Biliary Cancer
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)
- Details
ClinicalTrials.gov ID:
NCT06467357
Diagnosis Type:
NA
USOR Number:
- Address
,
P: